Format

Send to

Choose Destination
Cancer. 2015 Sep 1;121 Suppl 17:3113-21. doi: 10.1002/cncr.29551.

Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients.

Author information

1
Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
2
Shanghai Respiratory Research Institute, Shanghai, China.
3
Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
4
Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
5
State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China.

Abstract

BACKGROUND:

This study applied a combined cancer biomarker panel to clinically identify small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) in a high-risk population.

METHODS:

The serum levels of 4 biomarkers (progastrin-releasing peptide [ProGRP], carcinoembryonic antigen [CEA], squamous cell carcinoma antigen [SCC], and cytokeratin 19 fragment [CYFRA21-1]) were determined in 153 patients with a high risk of lung cancer (12 with a new diagnosis of SCLC, 52 with NSCLC, and 89 without lung cancer). Information about diagnosis delays was collected through interviews of all participants.

RESULTS:

Significantly higher serum levels of ProGRP (P < .0001) were found among the SCLC patients versus the rest of the population. A receiver operating characteristic curve analysis established the cutoff values of ProGRP, CEA, SCC, and CYFRA21-1 as 300 pg/mL, 7.3 ng/mL, 3 ng/mL, and 6.5 ng/mL, respectively. The sensitivity and specificity of ProGRP in diagnosing SCLC were 75% and 100%, respectively. Among the 14 lung cancer patients with a false-negative computed tomography (CT) result, the diagnostic panel detected 8 additional cancers.

CONCLUSIONS:

This panel increased the diagnostic specificity for high-risk subjects (those with renal failure being excluded), and auxiliary to a CT scan, it increased the sensitivity for patients with lung cancer. These results might be applied to shorten the diagnosis delay at health care institutions in China.

KEYWORDS:

biomarker; delayed diagnosis; non-small cell lung cancer; progastrin-releasing peptide (ProGRP); small cell lung cancer

PMID:
26331818
DOI:
10.1002/cncr.29551
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center